ETERGEN WHITE PAPER

Executive Summary I. Brief History II. The problem III. Solution – business model IV. Token offer V. Our Accountability with Your investments VI. Timeline VII. Our Team Disclamer

The ETERGEN Foundation – Live longer. Executive Summary

At Eternity foundation we believe that human life is precious. And we want you and

your loved ones to live longer.

In fact, we are doing everything we can for it, through supporting scientific research in

the field of human life extension.

With technology and knowledge our society has now, we all can live a longer, healthier

life, only if the needed attention was paid to the financing of the research in the field of life

extension.

We support international medical and scientific research, aimed at human life extension,

with system of grants and investments for the best projects.

We believe that significant human life extension can be reached within our lifetime.

To finance this research, we offer our own cryptocurrency, THE ETER.

THE ETER is state of the art cryptocurrency giving you the lowest cost per transaction

and true anonymous security .

Not only will the ETER help the mankind to solve the most important question we face,

but it will also create great value for all the currency holders, since every project, financed by

us, will have a contract obligation to share the profits with all the holders. This will be

guaranteed through use of smart contracts utilizing the blockchain technology.

"1

ETERGEN WHITE PAPER

We will build up the industry of human life extension through introducing cutting edge

technology.

Our key advantages are: A global projectA growing  multibillion industry with huge growth potentialReal value behind the currency Experienced team with high qualifications Unique idea - there is no other project like this.Your investments fully accountable for

I. Brief history Since the beginning of time, life extension has been the ultimate dream for mankind,

being mentioned as early as in the Sumerian Epic of Gilgamesh and the Egyptian medical

papyruses, all the way through the Ayurvedapractitioners, alchemists, hygienists such as Luigi

Cornaro, Johann Cohausen and Christoph Wilhelm Hufeland, and philosophers such

as Francis Bacon, René Descartes, Benjamin Franklin and Nicolas Condorcet. However, the

beginning of the modern period in this endeavor can be traced to the end of the 19th –

beginning of the 20th century, to the so-called "fin-de-siècle" (end of the century) period,

denoted as an "end of an epoch" and characterized by the rise of scientific optimism and

therapeutic activism, entailing the pursuit of life extension (or life-extensionism). Among the

foremost researchers of life extension at this period were the Nobel Prize winning

biologist Elie Metchnikoff (1845-1916) -- the author of the cell theory of immunity and vice

director of Institute Pasteur in Paris, and Charles-Édouard Brown-Séquard (1817-1894) -- the

president of the French Biological Society and one of the founders of modern endocrinology.

Sociologist James Hughes claims that science has been tied to a cultural narrative of

conquering death since the Age of Enlightenment. He cites Francis Bacon (1561–1626) as an

advocate of using science and reason to extend human life, noting Bacon's novel New

Atlantis, wherein scientists worked toward delaying aging and prolonging life. Robert

Boyle (1627–1691), founding member of the Royal Society, also hoped that science would

make substantial progress with life extension, according to Hughes, and proposed such

experiments as "to replace the blood of the old with the blood of the young". Biologist Alexis

"2

ETERGEN WHITE PAPER

Carrel (1873–1944) was inspired by a belief in indefinite human lifespan that he developed

after experimenting with cells.

In 1970, the American Aging Association was formed under the impetus of Denham

Harman, originator of the free radical theory of aging. Harman wanted an organization

of biogerontologists that was devoted to research and to the sharing of information among

scientists interested in extending human lifespan.

In 1976, futurists Joel Kurtzman and Philip Gordon wrote No More Dying. The

Conquest Of Aging And The Extension Of Human Life, (ISBN 0-440-36247-4) the first

popular book on research to extend human lifespan. Subsequently, Kurtzman was invited to

testify before the House Select Committee on Aging, chaired by Claude Pepper of Florida, to

discuss the impact of life extension on the Social Security system.

In 1983, Roy Walford, a life-extensionist and gerontologist, published a popular book

called Maximum Lifespan. In 1988, Walford and his student Richard Weindruch summarized

their research into the ability of calorie restriction to extend the lifespan of rodents in The

Retardation of Aging and Disease by Dietary Restriction. It has been kn own since the work

of Clive McCay in the 1930s that calorie restriction can extend the maximum lifespan of

rodents. But it was the work of Walford and Weindruch that gave detailed scientific

grounding to that knowledge .

In recent years, the discovery of internet accelerated scientific research in all fields, and

fundamental discoveries have been made in genetics and medicine, that place us within the

reach of a major breakthrough in life extension. However, we do have a major problem that

prevents us from it.

II. The Problem The problem is the lack of financing and coordination in human life extension . The

discovery needed to significantly extend our life span will come from cooperation in different

fields of science - the genetics, the biochemistry, the pharmacology. There is no serious effort

to develop this cooperation, and there is no planned financing of the most promising

research. There is a reason for that.

The sad truth is that the government does not want you to live after you reach the

retirement age. At this time you become a burden to the social security and medical care

system. In fact, if all of us lived 10 years longer, it will most likely bankrupt these systems.

"3

ETERGEN WHITE PAPER

If you check, how much money the governments are spending on the most important

goal the people have, life extension, the answer is shocking. It is zero. The government wants

you dead as soon as you are off the work force.

There is no broad private effort either. The big Pharma companies are not really

interested in you living a long and healthy life. If you think about it, they are interested in

profits, so for them your ideal state would be permanently sick( and dead the moment your

insurance is not capable to cover the drug payments). The private capital stays away from

financing the research because they do not see the immediate and sure return on the

investment. There is effort on the part of some companies or rich private individuals , but it is

damned by secrecy of the research and narrowness of it. And the worst case scenario for

mankind would be, if one of these private secretly funded projects succeeds, making the few

extremely rich living longer , and the masses left to die with no access to the discovery.

The problem is, put in simple words, that thousands of people are dying hourly, and

they should not be.

III. Solution - business model The Eternity foundation will organize and finance the scientific and medical research

worldwide for the fastest possible development of anti-aging and life extension drugs.

We will arrange the financing by distribution of crypto currency ETER , developed by

us. That will assure the security and accountability of all the funding.

"4

ETERGEN WHITE PAPER

The proceeds from the ICO would be used for financing the most promising projects in

the field. Each project we finance will have to provide the Eternal foundation with

participation in commercial rights for the project work.

This way we will create a tremendous value for all the holders of ETER, with

distributing it in the currency via the block-chain.

We will also invest in raising the public awareness on the importance of work in the field

of human life extension.

"5

ETERGEN WHITE PAPER

distribution of funds from ICO

60% financing the life extension research in medicine, pharmacology and genetics

through direct investment,

10% currency market maker

10% network upkeep

5% operating expenses

5% promoting the currency

5% building the public awareness

5% fees and commissions

IV. Token offer Initial token offer details

Before the ICO, we offer the investors the opportunity to participate in the token offer.

21.000.000 tokens will be distributed, at the cost of 1 ETH = 1000 tokens, 1 BTC =

10000 at the start of the offer.

The funds raised through token sale will be used to for ICO preparation .

Tokens will be distributed on the first come, first served basis. To buy the tokens, you

will have to open a wallet on our website and exchange the tokens for ethereum or bitcoin.

The minimum token sale is 100 tokens and the maximum is 10000 tokens.

Once the tokens are distributed, we will arrange for them to trade on an exchange.

Below is the breakdown of the token sale proceeds distribution

30% developing the currency technology

10%- legal costs

10% - listing the currency and tokens on the exchanges

10% - marketing fees, advertising, social media

20% management team

10% referral program

10% miscellaneous expenses

"6

ETERGEN WHITE PAPER

The tokens will be offered through our website from march 30 2018 till July 30th 2018,

while supply lasts.

The tokens can be used for payment for ETERGEN future products and services. The

tokens will also give buyers rights to vote using the blockchain technology on the key issues in

currency development. Each token holder will be able to participate at the pre ICO offer of

ETER currency .

V. Our Accountability with Your investments We believe that we have to be transparent with the contributors to the token sale

participants as well as the wider community. So, we will make sure that all parties are

informed on how we have spent the contributed resources which we will be collecting through

"7

ETERGEN WHITE PAPER

the token sale. Therefore, we propose to prepare a Business Report that will include

information regarding how we have spent the contributed money towards the development of

the project and its technologies at the end of each fiscal year. We will disclose the following

information in the Business Report to the public on our website:

1. Percentage of contributed amount spent in the preceding year, commencing

from the date of the conclusion of the token sale or the last report end date

2. Percentage of contributed amount spent on the currency development, in one

fiscal year, commencing from the date of the conclusion of the token sale or the last report

end date

3. Percentage of contributed amount spent on marketing and PR expenses, in

one fiscal year, commencing from the date of the conclusion of the sale or the last report end

date;

4. 4. Percentage of contributed amount spent on miscellaneous expenses in one

fiscal year, commencing from the date of the conclusion of the sale or the last report end

date.

VII. Timeline Token offer March 30th – July 30

Listing token on the exchange – Sept 1

Development of the crypto currency August 1 - Jan 30th 2019

ICO preparation – Nov 1 – Febr 28

Pre ICO to the token holders – March 1

ICO – March 30

VII. Our Team Andrej Jbankov, Ph.D.

CEO and founder

With PhD in technical studies, Mr. Jbankov has 25 years experience in the field of

computers, internet and international business.

"8

ETERGEN WHITE PAPER

Ilya Stavrovski , Ing., M.S.

Project management

With education in software engineering and operation research, Mr. Stavrovski has 25

year of experience in managing international projects in fields of high tech manufacturing,

finance and banking.

Boris Stavrovski

Ing, Ph.D, President

With PhD in technical studies, Boris Stavrovski brings 30 years of expertise in scientific

research with the extensive knowledge of game theory, statistics , probability theory and

cryptology.

Alex Bronshtejn

Head of medical research

Doctor Bronshtejn brings his knowledge of the medical and pharmacalogical research.

Alexander Antonov, M.D

Coordinator of clinical trials

Doctor Antonov is responsible for coordination of clinical trials and implementation.

Pavel Drumev, JD

Head of legal department and compliance

Disclaimer All information listed above is believed to be accurate, however ETERGEN foundation

or its employees will not be hold liable for any mistakes for any actions you take on the base

of it.

"9

ETERGEN WHITE PAPER

This paper is not an investment offer. It can not substitute for legal or investment advice.

The ETER and ETERGEN are registered trademarks of the ETERGEN foundation. The

ETER token is not an investment instrument under the laws of any country. Please check

your local rules and regulations to find out if you are eligible to take part in the token offer.

Void there prohibited.

Please note, that block-chain currencies and their derivatives, have been known for wide

fluctuations in value. Make well informed decisions and only risk the money you can afford

to loose without effecting your standard of life.

"10